REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This study is intended to provide readers with an understanding of the global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs. The study outlines the industry structure, competitive aspects, current developments, and future trends in the market, to assist in identifying areas of commercial interest and potential in the asthma and COPD indications. The objectives of the study include the assessment of current market status, the analysis of marketed drugs, market revenues, company shares, unmet market needs, market challenges, and future trends. Future market revenues are forecast for the global market, major drug classes, individual disease indication, and largest geographical regions. The study also reviews the compounds currently being investigated in clinical studies for the treatment of asthma and COPD.
REASONS FOR DOING THE STUDY
Asthma and chronic obstructive pulmonary disease are two diseases experiencing increasing prevalence globally due to a combination of factors, including the aging of the population and the rising pollution levels, particularly in emerging countries. COPD is one of the top five causes of disability and death in industrialized countries and the fourth-leading cause of death globally. The market for asthma and COPD drugs is large, with global revenues exceeding $25 billion in 2008, and projected to grow. Prescription drugs developed for these indications could enjoy tremendous commercial success; this is illustrated by the presence of six currently marketed multibillion-dollar drugs in this market. However, there is a rather high level of unmet needs in this market in terms of treatment options for asthma and COPD patients. Several new drugs are projected to enter the market through 2014 and are expected to drive the growth of revenues for asthma and COPD drugs.
SCOPE OF REPORT
The report intends to provide a current market snapshot and future developments in the asthma and COPD drugs market over the period from 2007 through 2014. The report describes existing drug classes approved for these indications, such as bronchodilators, anti-inflammatory drugs, and combination drugs of inhaled corticosteroids and bronchodilators. The pipeline of drugs in clinical trials for these indications is also presented and analyzed.
The report includes the following major sections:
- Disease overview
- Industry structure and competitive analysis, including tiers of competition, regulatory aspects, competitive factors, market unmet needs, challenges, and trends
- Overall market revenue forecast and current market shares as well as revenue forecast by major drug classes, disease indication, and geographical regions
- In-depth analyses of current drug classes as well as a profiles of major drugs
- Reviews and analyses of compounds in clinical trials, with an emphasis on drugs in advanced stages of development.
METHODOLOGY
The analyses and data presented in this report are based on information collected from a variety of industry sources, including pharmaceutical manufacturers and end users. Secondary information sources include company financials and documentation, SEC filings, trade organizations and publications, online databases, and medical and scientific literature.
The base year for analysis and forecast is 2008. Revenue forecasts are provided for the period 2009 to 2014. The forecasts are based on a comprehensive analysis of a variety of market and product-specific factors, including historical, current, and future trends; existing and undiagnosed patient population; unmet market needs; existing products patent expiration dates; the threat of generic substitution; new market entrants; and their value proposition and differentiation.
INTENDED AUDIENCE
This report provides information that is useful for business planners, market researchers, marketers, business developers, investors, venture capitalists, consultants, and anyone who wants to understand or invest in this market. The information is also useful for technology licensing and scientific research and development purposes.
INFORMATION SOURCES
The analysis and data presented in this report are based on information collected from a variety of industry sources, including the pharmaceutical manufacturers that currently market prescription drugs in this therapeutic area and research-based companies that develop new drug candidates for these indications, as well as end users of prescription drugs. Secondary information sources include company websites, financials, and other literature; U.S. Securities and Exchange Commission (SEC) filings; trade organizations and publications; online databases; and medical and scientific literature.
ANALYST CREDENTIALS
Adriana Rusu holds a Master of Business Administration and a Master of Arts in Chemistry degrees from the University of Arizona. She has more than 6 years of experience in market analysis and management consulting for the life-sciences industry. In her previous positions, Adriana consulted for various life-sciences industry players, including major pharmaceutical companies such as Pfizer, Johnson & Johnson, Novartis, and Merck. She has been quoted in various publications, including Pharma Drug Discovery, Chemistry and Industry, and Drug Discovery News. Adriana has also worked for several years in scientific research and development and quality control for the chemicals industry.
BCC ONLINE SERVICES
BCC offers an online information retrieval service. BCC’s home page, located at www.bccresearch.com, enables readers to:
- Examine BCC’s complete catalog of Market Research Reports and place direct orders
- Subscribe to any of BCC’s many industry newsletters
- Read announcements of recently published reports and newly launched newsletters
- Register for BCC’s well-known conferences
- Request additional information on any BCC product
- Take advantage of special offers
DISCLAIMER
The information developed in this report is intended to be as reliable as possible at the time of publication and of a professional nature. This information does not constitute managerial, legal, or accounting advice; nor should it serve as a corporate policy guide, laboratory manual, or an endorsement of any product, as much of the information is speculative in nature. The author assumes no responsibility for any loss or damage that might result from reliance on the reported information or its use.
